BBI
ESPR

Baxter Bros Inc’s Esperion Therapeutics ESPR Stock Holding History

Baxter Bros Inc’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,000
Closed -$9.84K – 166
2025
Q2 		$9.84K Hold
10,000
– – ﹤0.01% 151
2025
Q1 		$14.4K Sell
10,000
-5,000
-33% -$9.21K ﹤0.01% 148
2024
Q4 		$33K Buy
15,000
+4,000
+36% +$9.33K ﹤0.01% 156
2024
Q3 		$18.1K Hold
11,000
– – ﹤0.01% 154
2024
Q2 		$24.4K Buy
+11,000
New +$25.9K ﹤0.01% 155

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Baxter Bros Inc's ESPR Position: Q3 2025 in Review

Baxter Bros Inc sold out of Esperion Therapeutics (ESPR) in Q3 2025, closing a stake of 10,000 shares — an estimated $9.84K sold.

Baxter Bros Inc first reported a position in ESPR in Q2 2024 and held it in 5 quarters. The position peaked at $33K in Q4 2024. 188 funds tracked by Wall St. Rank hold ESPR as of Q3 2025.

  • Baxter Bros Inc reported no remaining Esperion Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Baxter Bros Inc sold 10,000 Esperion Therapeutics shares in Q3 2025, an estimated $9.84K.
  • Baxter Bros Inc first reported a position in Esperion Therapeutics in Q2 2024 and held it in 5 quarters.
  • Baxter Bros Inc's Esperion Therapeutics position peaked at $33K in Q4 2024.
  • 188 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2025.

Based on Baxter Bros Inc's 13F filing for Q3 2025, filed 14 Oct 2025.